Denileukin diftitox

Denileukin diftitox
Clinical data
Trade namesOntak, others
AHFS/Drugs.comMonograph
MedlinePlusa611024
License data
Routes of
administration		Intravenous
Drug classAntineoplastic
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life70-80 min
Identifiers
IUPAC name
  • Diphtheria toxin-Interleukin-2 fusion protein
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2560H4042N678O799S17
Molar mass57647.46 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.[3]

Medical uses

Denileukin diftitox is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.[1][2]

Adverse effects

The prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.[1][2]

Society and culture

In 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.[1][4]

References

  1. ^ a b c d "Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999". DailyMed. Retrieved 9 August 2024.
  2. ^ a b c fda.gov
  3. ^ Turturro F (January 2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Review of Anticancer Therapy. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. S2CID 9028829.
  4. ^ Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 (11): 1445–51. doi:10.1517/14712590903348135. PMID 19817678. S2CID 23956460.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.